Abcam opens new U.S.-based manufacturing facility

By The Science Advisory Board staff writers

July 13, 2021 -- Abcam has opened a new 100,000-sq-ft facility in Waltham, MA, to serve as a hub for its research and development (R&D) and commercial activities in the region.

The facility will more than double Abcam's capacity at its previous site in Cambridge, MA, and will eventually house about 300 employees, according to the company. The new site will increase the company's flexibility, scale, and capacity in R&D, production, distribution, and customer service for biopharma partners and life science researchers.

Abcam provides reagents to support development of diagnostics, vaccines, and potential therapeutics.

Cancer Research UK, Abcam partner on cancer antibodies
Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used...
The “Two-Headed Monster”: Vendors Tackle Antibody Validation
The Science Advisory Board examined the preferences of scientists regarding the purchase and use of antibodies, as well as customer trust, satisfaction,...

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter